Huebel, K., Strati, P., Sehn, L., Wu, J., Colucci, P., Bortolami, O., Scholz, C. (2025). Phase 3 study (inMIND) of tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Clinical characteristics and outcomes of high-risk patients. Blood. https://doi.org/10.1182/blood-2025-5367